More Than 30 Federal Agencies Buy From This Cybersecurity Tech

In January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.

Click here to learn how a small company is joining the ranks of Lockheed Martin and Raytheon

Philip L. Johnson net worth and biography

Philip Johnson Biography and Net Worth

CFO of Jazz Pharmaceuticals

Mr. Johnson was appointed chief financial officer in March 2024. Mr. Johnson brings extensive experience in global financial leadership roles within the pharmaceutical industry, as a management consultant, and as an investment banker in the U.S. and Europe. Throughout his career, he’s taken on finance roles of increasing responsibility while gaining experience around the world including in Japan, Latin America, Spain, Italy and the U.S. Mr. Johnson is also committed to community and social impact efforts and serves on a variety of community boards of directors.

From January 2018 to February 2024, Mr. Johnson served as group vice president and treasurer of Eli Lilly and Company. Joining Eli Lilly and Company in 1995, Mr. Johnson served in a variety of roles, increasing in responsibility, culminating in his role as group vice president and treasurer. Prior to his career at Lilly, Mr. Johnson served as a management consultant for McKinsey & Co. and worked with investment banks in Milan, Italy and Chicago, Illinois. Mr. Johnson received a B.S from the University of Illinois and a Master of Management from the Kellogg School of Management at Northwestern University.

What is Philip L. Johnson's net worth?: The estimated net worth of Philip L. Johnson is at least $3.06 million as of March 1st, 2024. Mr. Johnson owns 27,932 shares of Jazz Pharmaceuticals stock worth more than $3,063,582 as of September 16th. This net worth estimate does not reflect any other investments that Mr. Johnson may own. Learn More about Philip L. Johnson's net worth.
How do I contact Philip L. Johnson?: The corporate mailing address for Mr. Johnson and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Philip L. Johnson's contact information.
Has Philip L. Johnson been buying or selling shares of Jazz Pharmaceuticals?: Philip L. Johnson has not been actively trading shares of Jazz Pharmaceuticals during the past quarter. Most recently, on Friday, March 1st, Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock. The stock was acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. Learn More on Philip L. Johnson's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 5 times. They sold a total of 8,926 shares worth more than $1,000,050.92. The most recent insider tranaction occured on September, 6th when SVP Mary Elizabeth Henderson sold 1,410 shares worth more than $152,703.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 9/6/2024.

Philip L. Johnson Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/1/2024	Buy	12,000	$119.65	$1,435,800.00	27,932

Philip L. Johnson Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $109.68

$109.34

$110.55

50 Day Range

MA: $110.03

$100.57

$116.37

2 Week Range

Now: $109.68

$99.06

$137.38

Volume

293,984 shs

Average Volume

686,128 shs

Market Capitalization

$6.92 billion

P/E Ratio

22.61

Dividend Yield

N/A

Beta

0.57